

<https://helda.helsinki.fi>

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder

Mazumder, Atiqul Haq

Multidisciplinary Digital Publishing Institute

2021-05-23

Mazumder, A.H.; Barnett, J.; Lindberg, N.; Torniainen-Holm, M.; Lähteenvuori, M.; Lahdensuo, K.; Kerkelä, M.; Hietala, J.; Isometsä, E.; Kampman, O.; Kieseppä, T.; Jukuri, T.; Häkkinen, K.; Cederlöf, E.; Haaki, W.; Kajanne, R.; Wegelius, A.; Männynsalo, T.; Niemi-Pynttari, J.; Suokas, K.; Lönnqvist, J.; Niemelä, S.; Tiihonen, J.; Paunio, T.; Palotie, A.; Suvisaari, J.; Veijola, J. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder. *Brain Sci.* 2021, 11, 688.

<http://hdl.handle.net/10138/330233>

Downloaded from Helda, University of Helsinki institutional repository.




This is an electronic reprint of the original article.

This reprint may differ from the original in pagination and typographic detail.

Please cite the original version.

Article

Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder

Atiqul Haq Mazumder ^{1,*} , Jennifer Barnett ², Nina Lindberg ³, Minna Torniainen-Holm ⁴, Markku Lähteenvuo ^{5,6,†}, Kaisla Lahdensuo ^{6,7,†}, Martta Kerkelä ¹ , Jarmo Hietala ^{8,9}, Erkki Isometsä ³, Olli Kampman ^{10,11} , Tuula Kieseppä ^{3,6,7,†}, Tuomas Jukuri ^{1,6,†}, Katja Häkkinen ^{5,6,†}, Erik Cederlöf ⁴, Willehard Haaki ^{6,8,†}, Risto Kajanne ⁶, Asko Wegelius ^{3,4,6,†}, Teemu Männynsalo ^{6,12,†}, Jussi Niemi-Pynttari ^{6,12,†}, Kimmo Suokas ^{6,10,†}, Jouko Lönnqvist ^{4,13}, Solja Niemelä ^{8,9}, Jari Tiihonen ^{5,14,15}, Tiina Paunio ^{3,4,13}, Aarno Palotie ^{6,7,16,17,†}, Jaana Suvisaari ⁴ and Juha Veijola ^{1,18}

- ¹ Department of Psychiatry, University of Oulu, 90014 Oulu, Finland; Martta.Kerkela@oulu.fi (M.K.); Tuomas.Jukuri@oulu.fi (T.J.); juha.veijola@oulu.fi (J.V.)
- ² Cambridge Cognition, University of Cambridge, Cambridge CB25 9TU, UK; jhb32@cam.ac.uk
- ³ Department of Psychiatry, Helsinki University Hospital, University of Helsinki, 00029 Helsinki, Finland; nina.lindberg@helsinki.fi (N.L.); erkki.isometsa@helsinki.fi (E.I.); tuula.kieseppa@helsinki.fi (T.K.); asko.wegelius@fimnet.fi (A.W.); tiina.paunio@helsinki.fi (T.P.)
- ⁴ Mental Health Unit, Finnish Institute for Health and Welfare (THL), 00271 Helsinki, Finland; minna.torniainen-holm@thl.fi (M.T.-H.); erik.cederlof@thl.fi (E.C.); jouko.lonnqvist@thl.fi (J.L.); jaana.suvisaari@thl.fi (J.S.)
- ⁵ Department of Forensic Psychiatry, Niuvanniemi Hospital, University of Eastern Finland, 70240 Kuopio, Finland; Markku.Lahteenvuo@niuva.fi (M.L.); Katja.Hakkinen@niuva.fi (K.H.); jari.tiihonen@ki.se (J.T.)
- ⁶ Institute for Molecular Medicine Finland (FIMM), University of Helsinki, 00014 Helsinki, Finland; kaisla.lahdensuo@icloud.com (K.L.); hawker@utu.fi (W.H.); risto.kajanne@helsinki.fi (R.K.); teemu.mannynsalo@hel.fi (T.M.); jussi.niemi-pynttari@hel.fi (J.N.-P.); kimmo.suokas@tuni.fi (K.S.); aarno.palotie@helsinki.fi (A.P.)
- ⁷ Mehiläinen, Pohjoinen Hesperiankatu 17 C, 00260 Helsinki, Finland
- ⁸ Department of Psychiatry, University of Turku, 20014 Turku, Finland; jarmo.hietala@tyks.fi (J.H.); solnie@utu.fi (S.N.)
- ⁹ Department of Psychiatry, Turku University Hospital, 20521 Turku, Finland
- ¹⁰ Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland; olli.kampman@tuni.fi
- ¹¹ Department of Psychiatry, Pirkanmaa Hospital District, 33521 Tampere, Finland
- ¹² Social Services and Health Care Sector, City of Helsinki, 00099 Helsinki, Finland
- ¹³ Department of Psychiatry, University of Helsinki, 00014 Helsinki, Finland
- ¹⁴ Department of Clinical Neuroscience, Karolinska Institute, 17177 Stockholm, Sweden
- ¹⁵ Center for Psychiatry Research, Stockholm City Council, 11364 Stockholm, Sweden
- ¹⁶ Stanley Center for Psychiatric Research, The Broad Institute of MIT (Massachusetts Institute of Technology) and Harvard, Cambridge, MA 02142, USA
- ¹⁷ Analytical and Translational Genetics Unit, Massachusetts General Hospital, Boston, MA 02114, USA
- ¹⁸ Department of Psychiatry, Oulu University Hospital, 90220 Oulu, Finland
- * Correspondence: atiqul.mazumder@oulu.fi or atiq10@gmail.com
- † Years 2016–2018.



Citation: Mazumder, A.H.; Barnett, J.; Lindberg, N.; Torniainen-Holm, M.; Lähteenvuo, M.; Lahdensuo, K.; Kerkelä, M.; Hietala, J.; Isometsä, E.; Kampman, O.; et al. Reaction Time and Visual Memory in Connection with Alcohol Use in Schizophrenia and Schizoaffective Disorder. *Brain Sci.* **2021**, *11*, 688. <https://doi.org/10.3390/brainsci11060688>

Academic Editor: Gary Donohoe

Received: 15 April 2021

Accepted: 21 May 2021

Published: 23 May 2021

Publisher's Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Copyright: © 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<https://creativecommons.org/licenses/by/4.0/>).

Abstract: The purpose of this study was to explore the association between cognition and hazardous drinking and alcohol use disorder in schizophrenia and schizoaffective disorder. Cognition is more or less compromised in schizophrenia, and schizoaffective disorder and alcohol use might aggravate this phenomenon. The study population included 3362 individuals from Finland with diagnoses of schizophrenia or schizoaffective disorder. Hazardous drinking was screened with the AUDIT-C (Alcohol Use Disorders Identification Test for Consumption) screening tool. Alcohol use disorder (AUD) diagnoses were obtained from national registrar data. Participants performed two computerized tasks from the Cambridge Automated Neuropsychological Test Battery (CANTAB) on a tablet computer: The Five-Choice Serial Reaction Time Task (5-CSRTT) or the reaction time (RT) test and the Paired Associative Learning (PAL) test. The association between alcohol use and the RT and PAL tests was analyzed with log-linear regression and logistic regression, respectively. After

adjustment for age, education, housing status, and the age at which the respondents had their first psychotic episodes, hazardous drinking was associated with a lower median RT in females and less variable RT in males, while AUD was associated with a poorer PAL test performance in terms of the total errors adjusted scores (TEASs) in females. Our findings of positive associations between alcohol and cognition in schizophrenia and schizoaffective disorder are unique.

Keywords: cognition; visual memory; reaction time; alcohol; schizophrenia; schizoaffective disorder

1. Introduction

Cognitive dysfunction is a persistent, disabling hallmark of schizophrenia found to be present in approximately 75% of schizophrenia patients [1]. It is associated with the severity of illness in schizophrenia [2]. Schizophrenia patients with comorbid AUD demonstrate a marked impairment in multiple cognitive domains [3–7]. The most affected cognitive domains are sustained attention, concept formation, and non-verbal cognitive flexibility [8,9].

Individuals with schizophrenia have a three-times greater risk of heavy alcohol use than the general population [10]. AUD is the second most common comorbidity in patients with schizophrenia, after nicotine dependence [11]. A systematic review and meta-analysis of 123 research papers published between 1990 and 2017 revealed a lifetime prevalence of AUD of 24.3% among subjects with schizophrenia [12].

Approximately 90% of people who drink excessively would not be expected to meet the clinical diagnostic criteria for having AUD [13]; however, they could screen positive for hazardous drinking or binge (heavy episodic) drinking.

Hazardous drinking is a pattern of alcohol consumption that increases the risk of harmful consequences for the user or others. Hazardous drinking patterns are of public health significance, irrespective of the absence of any current disorder in the individual alcohol user [14–17].

In the general population, males drink more alcohol than females [18]. However, in recent years, the male-to-female ratios for alcohol use, problematic alcohol use, and alcohol-related harm have declined considerably [19,20].

Studies in general populations suggest that mild-to-moderate alcohol drinking might not reduce cognition [21–24]. In schizophrenia patients, the association between cognition and different drinking patterns has not been fully studied yet.

The main aim of the present study was to explore the association between reaction time and visual memory with different drinking patterns in persons with schizophrenia and schizoaffective disorder diagnoses.

The specific research aims were to study the following:

1. The association between hazardous drinking and reaction time and visual memory in persons with schizophrenia and schizoaffective disorder.
2. The association between alcohol use disorder and reaction time and visual memory in persons with schizophrenia and schizoaffective disorder.

2. Materials and Methods

2.1. Participants

The participants of this study were part of the study population of SUPER (*Suomalainen psykoosisairauksien perinnöllisyysmekanismien tutkimus* (“Finnish Study of the Hereditary Mechanisms behind Psychotic Illnesses”)), which is part of the international Stanley Global Neuropsychiatric Genomics Initiative, USA. SUPER collected data during the period 2016–2019 from people with a lifetime diagnosis of psychosis in Finland to identify gene loci and gene variations predisposing patients to psychotic illnesses and comorbid diseases. Voluntary subjects with a diagnosis of schizophrenia spectrum psychotic disorder, bipolar I disorder, or major depressive disorder with psychotic features were recruited from psy-

chiatric inpatient and outpatient departments, general healthcare centers, and supported housings. Participants were identified through local healthcare centers throughout the country from all levels of healthcare to ensure inclusive sampling. Subjects were also recruited via advertisements in local newspapers.

Out of the original sample of 10,555 participants, 6769 had clinical diagnoses of schizophrenia and schizoaffective disorder. Among those, 228 had missing information on alcohol use or education. Of the remaining 6541 participants, 1435 did not complete the cognitive tests or had duplicate test results. Finally, 3362 participants were included after excluding 1744 who did not live independently (living in supported housing, a hospital, or an unknown residence), as alcohol use is restricted in these places (Figure 1).




Figure 1. Flowchart showing the selected study population.

2.2. Schizophrenia and Schizoaffective Disorder Diagnoses

The diagnoses of schizophrenia and schizoaffective disorder were obtained from the Care Register for Health Care (CRHC) of the Finnish Institute for Health and Welfare. Upon fulfilling the diagnostic criteria, clinical diagnoses were made by clinicians, mostly in specialized care by psychiatrists, and the validity of the CRHC-based psychosis diagnoses was found to be good [25]. In Finland, the International Classification of Disease (ICD) system is used in psychiatric diagnoses. In this study, schizophrenia diagnoses included codes 295, according to ICD-8 and ICD-9, and F20, according to ICD-10, while schizoaffective

fective disorder diagnoses included codes 295.7, according to ICD-8 and ICD-9, and F25, according to ICD-10. ICD-8 was used from 1968 to 1986 and ICD-9 from 1987 to 1995, while ICD-10 has been used since 1996 in Finland.

2.3. Hazardous Drinking Screening

Hazardous drinking was screened using the AUDIT-C questionnaire to assess an individual's alcohol consumption frequency ("How often do you have a drink containing alcohol?"), quantity ("How many drinks containing alcohol do you have on a typical day when you are drinking?"), and bingeing ("How often do you have six or more drinks on one occasion?"). AUDIT-C is derived from the hazardous alcohol use domain of the Alcohol Use Disorders Identification Test (AUDIT) questionnaire [26]. It has three questions and is scored on a scale of 0 to 12. Each AUDIT-C question has five answer choices valued from zero to four points.

Cutoff scores for hazardous drinking vary considerably [26,27]. In the present study, we used the cutoff scores recommended by Finnish National Guidelines: a score of 6 or more in males and 5 or more in females [28].

2.4. Alcohol Use Disorder Diagnoses

The diagnoses of alcohol use disorder were obtained from the CRHC data according to codes ICD-8 291 and 303; ICD-9 291, 3030, and 3050A; and ICD-10 F10 for the period from 1969 to 2018.

2.5. Cognitive Measures

Processing speed and visual learning are the two core cognitive domains that are compromised in schizophrenia [29]; thus, we selected the Five-Choice Serial Reaction Time Task (5-CRTT) and the Paired Associative Learning (PAL) task from the Cambridge Neuropsychological Test Automated Battery (CANTAB) for schizophrenia for the assessment of reaction time (RT) and visual memory, respectively.

These tasks were chosen to produce relevant information on cognition in psychotic disorders in the very restricted assessment schedule. The instructions for both tests were translated into Finnish. The CANTAB tests were performed before venipuncture in order to avoid malfunction of the arm due to pain or bandaging. The study nurses were given standardized instructions on how to guide the study subjects in performing the CANTAB test beforehand.

In the RT test, we used two continuous measurements: the median of the five-choice reaction time and the standard deviation (SD) of the five-choice reaction time. The median of the five-choice reaction time is the median duration between the onset of the stimulus and the release of the button. The standard deviation of the five-choice reaction time is the standard deviation of the time taken to touch the stimulus after the button has been released. Both variables were calculated for correct, assessed trials where the stimulus could appear in any of the five locations.

In the PAL test, we assessed visual memory using the primary outcome variable of "total errors adjusted". Here, we assessed two different dichotomized variables using data from the Northern Finland Birth Cohort 1966 (NFBC 1966) as reference data [30]. The NFBC 1966 consists of all children born with an expected date in the year 1966. The data used in this study consisted of a 46-year follow-up, when cohort members took the PAL test during clinical examination ($N = 5608$). For the first trial memory score, the 15th percentile (a score of 17 or more) was used as a cutoff for good performance in the PAL test in the recent study, meaning the SUPER population showed better performance than 15% of the NFBC 1966 study population. Regarding the scores for total errors adjusted for the NFBC 1966, the 50th percentile (an error score of 10 or less) was used as a cutoff for good performance in the PAL test in a recent study, meaning the SUPER population exhibited better error scores than 50% of the NFBC 1966 study population. The distribution of the PAL test is problematic, with multiple peaks. It does not follow any known distribution and thus

we could not use a continuous distribution of PAL test variables. The first trial memory score shows how many patterns the participant correctly placed on the first attempt at each problem, while the total errors adjusted score reflects how quickly the participant learned when the participant was given multiple attempts at each problem.

2.6. Confounding Factors

Age, education [31], living without a spouse [32], and the age of a person at their first psychotic episode [4] have effects on cognitive functioning, and thus we considered them as the confounding variables in this study.

2.6.1. Age

Cognition is negatively associated with increased age in healthy populations [33] and debatably in alcohol users [34]. The age of the participants was calculated using the participation date and year of birth of the participant. Age was used as continuous variable.

2.6.2. Education

Education is strongly associated with cognitive performance [35]. The question and possible answers addressing the education of the participants were as follows: “What is your basic education?” (1 = less than primary school, 2 = matriculation examination, 3 = middle school, 4 = partial general upper secondary school or general upper secondary education certificate, 5 = partial middle school or primary school less than nine years, 6 = primary school, 7 = four-year elementary school). During the analysis, we combined classes 1, 3, 4, 5, 6, and 7 as “No matriculation examination” versus class 2 (“Matriculation examination”).

2.6.3. Household Pattern

Household patterns, especially living without a spouse, might affect cognition [32,36], and thus we considered household patterns as a confounder.

2.6.4. Age of First Psychotic Episode

We used the age of participants at their first psychotic episode as a marker of the severity of illness. Research shows that the earlier the development of schizophrenia and schizoaffective disorder, the more severe the illness in terms of the disease pattern and cognitive decline [37,38]. The data regarding the age of people at the time of their first psychotic episode were obtained from the CRHC and were used in this research as a continuous variable.

2.7. Statistical Methods

We evaluated the association between cognition and alcohol use by using four different cognition variables: the median and standard deviation of RT, PAL FTMS, and PAL with total errors adjusted. Alcohol use was measured with different variables: the dichotomous hazard drinking variable was derived from the AUDIT score and the dichotomous variable indicated if the study subject had an alcohol use disorder diagnosis. We assessed crude models and also adjusted models with age, education, household patterns, and age of participants at the time of their first psychosis episode. The association between the RT test and alcohol use was analyzed with log-linear regression and $e\beta$ with 95% confidence intervals (CI) are reported. The association between the PAL test and alcohol use was analyzed with logistic regression and odds ratios (ORs) with 95% CIs are reported.

All the analyses were conducted separately for males and females. Males and females showed differences in performing the selected cognitive tests [39–41]; additionally, males and females showed differences in alcohol use patterns [42].

3. Results

3.1. Background Factors and Alcohol Use Patterns

Of the participants, 51% were male and 49% were female. The mean age was 45 years for males and 46 years for females. One-third of the males and two-fifths of the females had the highest basic educational level of 12 years (matriculation). The mean age at the time of the first psychotic episode was 27 years for males and 28 for females. One-tenth of the males and one-fourth of the females were living with a spouse. Most of the participants were on psychotropic medication (Table 1).

Table 1. Background factors and alcohol use patterns in schizophrenia and schizoaffective disorder.

	Male	Female
	N = 1711	N = 1651
Age (mean (SD))	44.5 (12.8)	46.3 (13.2)
Education		
No matriculation examination (%)	1191 (69.6)	981 (59.4)
Matriculation examination (%)	520 (30.4)	670 (40.6)
Age of first psychotic episode (mean (SD))	26.84 (8.25)	28.01 (9.51)
Household patterns		
With spouse	200 (11.7)	441 (26.7)
Other	1511 (88.3)	1210 (73.3)
Current psychotropic medications		
No (%)	42 (2.45)	33 (2.00)
Yes (%)	1668 (97.49)	1614 (97.76)
Missing (%)	1 (0.06)	4 (0.24)
Hazardous drinking *		
No (%)	1276 (74.6)	1390 (84.2)
Yes (%)	435 (25.4)	261 (15.8)
Alcohol use disorder		
No (%)	1212 (70.8)	1395 (84.5)
Yes (%)	499 (29.2)	256 (15.5)

* AUDIT-C cutoff scores for hazardous drinking were ≥ 6 for males and ≥ 5 for females.

All types of alcohol use patterns were more common in males than in females. Every fourth male and every sixth female schizophrenia or schizoaffective disorder patient showed a positive screening for hazardous drinking. Approximately one-third of male and one-sixth of female schizophrenia or schizoaffective disorder patients had a lifetime diagnosis of AUD (Table 1).

Lower age was associated with hazardous drinking, both in males and females. In females, a lower age of onset and types of household were associated with hazardous drinking (see Supplementary Materials, Table S1).

The median RT was 435 ms (SD = 50 ms); the PAL median FTMS was 8 and the median total errors adjusted was 33 (see Supplementary Materials, Table S2).

The association between background factors and AUD with RT *p*-values is reported in the Supplementary Materials, Table S3. The association between background factors and alcohol use patterns with PAL scores is reported in the Supplementary Materials, Tables S4 and S5.

The Cohen's *d* measure of effect size is shown in the Supplementary Materials, Table S7. The effect sizes were in line with our results (significant results were found for male hazardous drinking RTI SD ($p = 0.008$; Cohen's $d = 0.22$), female RTI median ($p = 0.016$;

Cohen's $d = 0.31$ (0.18–0.44)), and female PAL TEA alcohol use disorder ($p = 0.048$; Cohen's $d = 0.12$)).

3.2. Association between Reaction Time and Visual Memory and Hazardous Drinking in Schizophrenia and Schizoaffective Disorder

After adjustment for age, education, household patterns, and age at the time of the first psychotic episode, hazardous drinking was associated—in females—with a lower median RT (OR = 0.97; 95% CI, 0.95–0.99) and in males with a less variable reaction time (Table 2). The association between hazardous drinking and RT scores is reported in the Supplementary Materials, Table S6.

Table 2. Association between RT and PAL tests and hazardous drinking in schizophrenia and schizoaffective disorder.

Five-Choice Reaction Time *					Five-Choice Reaction Time *			
Median					SD			
Crude			Adjusted ^a		Crude		Adjusted ^a	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Male								
Hazardous drinking	0.97 (0.95–0.99)	0.002	0.99 (0.97–1.01)	0.379	0.86 (0.81–0.91)	<001	0.93 (0.88–0.98)	0.008
Female								
Hazardous drinking	0.94 (0.92–0.97)	<0.001	0.97 (0.95–0.99)	0.016	0.89 (0.83–0.96)	0.002	0.99 (0.92–1.06)	0.760
PAL first trial memory score **					PAL total errors adjusted score **			
Better performance than 15% of NFBC 1966 members					Higher error scores than 50% of NFBC 1966 members			
Crude			Adjusted ^a		Crude		Adjusted ^a	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Male								
Hazardous drinking	1.76 (1.13–2.66)	0.001	1.24 (0.74–2.02)	0.399	0.56 (0.43–0.73)	<0.001	0.92 (0.67–1.28)	0.253
Female								
Hazardous drinking	1.58 (0.95–2.52)	0.064	1.02 (0.60–1.71)	0.893	0.58 (0.43–0.80)	<0.001	0.97 (0.75–1.34)	0.743

^a Adjusted for age, education, household patterns, and age at the time of the first psychotic episode. * Analyzed with log-linear regression.

** Analyzed with logistic regression.

3.3. Association between Reaction Time and Visual Memory and Alcohol Use Disorder in Schizophrenia and Schizoaffective Disorder

There was no significant difference in reaction times between male and female schizophrenia and schizoaffective disorder patients with or without a lifetime history of alcohol use disorder (Table 3).

Table 3. Association between RT and PAL tests and alcohol use disorder in schizophrenia and schizoaffective disorder.

	Five-Choice Reaction Time *				Five-Choice Reaction Time *			
	Median		SD		Median		SD	
	Crude		Adjusted ^a		Crude		Adjusted ^a	
	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value	OR (95% CI)	<i>p</i> -value
Male								
Alcohol use disorder	1.01 (0.99–1.02)	0.545	1.00 (0.99–1.02)	0.871	1.02 (0.96–1.08)	0.482	1.00 (0.95–1.06)	0.899
Female								
Alcohol use disorder	0.99 (0.96–1.01)	0.246	0.99 (0.96–1.01)	0.225	1.03 (0.96–1.11)	0.413	1.04 (0.97–1.11)	0.324

Table 3. Cont.

	Five-Choice Reaction Time *				Five-Choice Reaction Time *			
	Median				SD			
	PAL first trial memory score **				PAL total errors adjusted score **			
	Better performance than 15% of NFBC 1966 members				Higher error scores than 50% of NFBC 1966 members			
	Crude		Adjusted		Crude		Adjusted	
	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value	OR (95% CI)	p-value
Male								
Alcohol use disorder	0.71 (0.45–1.09)	0.131	0.83 (0.46–1.45)	0.543	1.36 (1.05–1.77)	0.021	1.18 (0.84–1.67)	0.358
Female								
Alcohol use disorder	0.53 (0.28–0.94)	0.043	0.62 (0.29–1.17)	0.102	1.57 (1.13–2.22)	0.009	1.34 (1.02–1.93)	0.048

^a Adjusted for age, education, household patterns, and age at the time of the first psychotic episode. * Analyzed with log-linear regression.

** Analyzed with logistic regression.

Females performed more poorly in the PAL test in terms of the total errors adjusted score after adjustment for age, education, household pattern, and age at first psychotic episode (OR = 1.34; 95% CI, 1.02–1.93) (Table 3).

4. Discussion

4.1. Main Findings

Our findings did not support our hypothesis that problematic drinking was associated with impaired cognitive function in schizophrenia and schizoaffective disorder. Rather, some positive associations were found between hazardous drinking and reaction time scores, both in males and females.

4.2. Comparison with Other Studies

There are hardly any studies investigating the association of different alcohol use patterns in schizophrenia and schizoaffective disorder patients; thus, it is difficult to compare our findings with other studies.

Most studies investigating the cognitive impact of alcohol in schizophrenia patients with comorbid AUD revealed a negative association between alcohol use and cognitive function [6,7,43–46]. On the contrary, some studies have suggested that AUD has no additive effects on cognitive impairment in schizophrenia patients [47–49] or has positive associations with social cognition [50–53], task-making, and the speed processing domains [54].

A meta-analysis of six studies published between 1996 and 2009 revealed that younger (<30 years) schizophrenia patients with comorbid alcohol use disorders have better cognition than schizophrenia patients without AUD. By contrast, older (>40 years) schizophrenia patients with comorbid alcohol use disorders have worse cognition than their non-comorbid counterparts [5]. A systematic review of research papers published between 1990 and 2012 revealed that cognition is more preserved in schizophrenia patients with comorbid substance/alcohol use disorders compared to schizophrenia patients without comorbidity [55]. It is likely that unmeasured confounding factors contributed to the discrepant findings in previous studies.

General population cross-sectional studies investigating the effects of alcohol on cognitive function have revealed that moderate-to-heavy drinking is associated with cognitive decline [56–59], while mild-to-moderate drinking is associated with either no effects on cognition [60,61] or cognitive enhancement [61–65].

Most cohort studies in the general population addressing the same issue have revealed a positive correlation between light/light-to-moderate alcohol use and cognitive function [23,24,66–68], whereas one cohort study found no association between light-to-

moderate alcohol consumption and better or worse cognitive functions [69–71]. One study reported a positive association between moderate-to-heavy drinking and cognitive function [72]. By contrast, another cohort study revealed a negative association between heavy alcohol use and cognitive function in a normal population [73]. One cohort study found a dose-dependent positive association for alcohol use and cognition compared to abstainers and former drinkers [74]. Another cohort study revealed significant cognitive impairment in low-functioning non-drinkers and light-to-moderate drinkers and high-functioning non-drinkers [75].

A brief review of 29 studies (2003–2013) revealed that acute alcohol use mostly impairs executive functioning in the normal population [76]. By contrast, a systematic review of 143 studies (1977–2011) revealed that light-to-moderate alcohol use does not impair cognition in young male and female individuals and reduces the risk of all forms of dementia and cognitive decline in older individuals [77]. Another systematic review of 28 reviews (2000–2017) revealed that light-to-moderate alcohol use in middle-to-late adulthood is associated with a decreased risk of cognitive impairment and dementia [22]. A meta-analysis of 27 cohort studies (2007–2018) revealed that moderate alcohol use improves cognition insignificantly among males and slightly among females compared to current non-drinkers [21]. Moderate alcohol use has been found to be associated with reduced amyloid-beta deposition in the human brain [78].

Study findings suggesting a positive association between alcohol use and cognition could be attributed to unmeasured or residual confounding factors [79,80], such as smoking [81], drink types [82], drinking patterns [83], personality [81,84], intelligence [70,85,86], educational attainment [87,88], potential abstainer errors [89–92], reverse causality bias [93], recall error [94], within-person temporal variation [95,96], ascertainment of diseases [97], and the sociability effect of alcohol [98]. Study findings suggesting a positive association between alcohol use and cognition could be attributed to poor motivation [99–101].

Some animal model studies found negative association between alcohol and cognition mediated by reductions in cell density in the cerebral cortex [102] and alterations of cholinergic interneurons in the Nucleus Accumbens [103]. Other animal model studies suggested positive association between alcohol and cognition thought to be mediated by enhancement of brain metabolite clearance [104] and activation of the vagus nerve [105], antioxidant system [106–109], and other biological processes [110–112]. However, none of these findings have thus far been confirmed to be causally important.

Epidemiological studies have suggested that the apparent beneficial effects of alcohol use might largely be non-causal [24,113–116]. More research is needed for further clarification [117].

4.3. Strengths

We were able to use a very large sample of schizophrenia and schizoaffective disorder patients to investigate the cognitive impact of different alcohol use patterns. We studied multiple alcohol use patterns in the same study population and used age, education, and age of onset of schizophrenia and schizoaffective disorder as potential confounding variables.

Although long-term antipsychotic medication might be associated with the additional loss of both gray and white matter in schizophrenia [118], in our study we did not confound antipsychotic medication because 98% of the study population was on antipsychotic medication; thus, it would not have made any statistically significant difference. First-generation antipsychotics have been found to be associated with an increased volume of the basal ganglia—namely, the globes pallidus—which might be reversed upon switching to second-generation antipsychotics and clozapine [119,120]. However, antipsychotic-induced brain volume loss has never been established to be associated with additional cognitive decline [121]. It was beyond the scope of this study to consider different types and different doses of psychotropic medication, because it would be extremely laborious to extract detailed data on medication and translate the prescription from Finnish to English. The use

of drug combinations was a further problem. In the original self-reporting questionnaire of SUPER, only conditions using or not using antipsychotic medication were included.

We included all schizophrenia and schizoaffective disorder patients living independently and excluded those whose living circumstances might have affected their alcohol use.

4.4. Limitations

We used only two tests from CANTAB. Our study was cross-sectional, not longitudinal. We did not use information about the onset of alcohol use, any recent changes in drinking habits, or any previous history of abstinence. We also did not differentiate previous alcohol users from people who never used alcohol.

We did not use information about poly-substance use and smoking. We did not include daily smoking as a covariate because of multicollinearity; approximately three-quarters of those with hazardous alcohol use in this sample were also daily smokers.

4.5. What Is Already Known on This Subject?

- Alcohol use disorder reduces cognition in schizophrenia and schizoaffective disorder patients.
- Mild alcohol use is not associated with impaired cognition in the normal population.

4.6. What Does This Study Add?

Hazardous drinking was not associated with cognitive deficits in schizophrenia and schizoaffective disorder.

5. Conclusions

Hazardous drinking was not associated with a cognitive decline in schizophrenia and schizoaffective disorder patients. Rather, some positive associations were found between hazardous drinking and cognition, which are unique to these psychiatric disorders but in line with the findings from general population studies. Further genetic epidemiological studies could help to resolve the correlation–causality–reverse causality debate regarding alcohol and cognition.

Supplementary Materials: The following supplementary tables are available online at <https://www.mdpi.com/article/10.3390/brainsci11060688/s1>, Table S1: Association between background factors and hazardous drinking in schizophrenia and schizoaffective disorder, Table S2: Distribution of RT median, RT SD, PAL first trial memory scores (FTMS), and PAL total error adjusted in the study population, Table S3: RT median and RT SD p-values for background factors and alcohol use disorder in schizophrenia and schizoaffective disorder, Table S4: PAL first trial memory scores (FTMS) for background factors and alcohol use patterns in schizophrenia and schizoaffective disorder, Table S5: PAL total error adjusted scores for background factors and alcohol use patterns in schizophrenia and schizoaffective disorder, Table S6: RT median and RT SD for hazardous drinking in schizophrenia and schizoaffective disorder.

Author Contributions: All authors contributed to the conception and design of the study, as well as to the collection of data from various sources. All authors were involved in the editing of the text and the discussion of the findings. All authors have read and agreed to the published version of the manuscript.

Funding: The work was supported by a grant from the Stanley Center for Psychiatric Research, Broad Institute, Cambridge, USA (grant agreement nos. 6045290-5500000710 and 6000009-5500000710). The principal author was supported by the Marie Skłodowska-Curie Action co-funding of regional, national, and international programs (COFUND) (grant agreement no. 713606) for his doctoral program (MSC-COFUND, I4FUTURE). The principal author was also supported by the Iso-Mällisen Foundation (Iso-Mällisen Säätiö) through a medical grant of EUR 4000 for the year 2019 (grant no. 0400 584622).

Institutional Review Board Statement: Prior to seeking study permissions, a statement pertaining to the ethical considerations of the study was requested from the Coordinating Ethics Committee of the Hospital District of Helsinki and Uusimaa, which is responsible for nationwide ethical statements. After receiving a favorable statement, permission to conduct the study was individually sought and obtained from all participating healthcare organizations. The Finnish Institute for Health and Welfare gave permission to access individual healthcare records in the registry data for which it is responsible (THL/1007/5.05.00/2017). The research was also conducted according to the guidelines of the following research ethics documents: The Responsible Conduct of Research and Procedures for Handling Allegations of Misconduct in Finland (http://www.tenk.fi/sites/tenk.fi/files/HTK_ohje_2012.pdf, accessed on 28 October 2020) and The European Code of Conduct for Research Integrity, revised edition 2017 (<http://www.tenk.fi/sites/tenk.fi/files/ALLEA-European-Code-of-Conduct-for-Research-Integrity-2017.pdf>, accessed on 28 October 2020).

Informed Consent Statement: Written informed consent was obtained from all participants. They were informed that participating in or abstaining from the study would not affect their treatment. The study subjects were also informed that they could withdraw their consent at any time, at which point any samples or data stored from them would be destroyed. Data already used in analyses, if not possible to remove from the completed analyses, would never be used in the future, unless part of a large summary dataset. If the subject was under involuntary psychiatric care or the study nurse had any doubts regarding the subject's ability to give informed consent, permission was sought to contact the attending physician of the subject to obtain a statement regarding whether the subject was able to give informed consent to participate in the study. Patients under guardianship were excluded from the study, as well as all minors. From all the study participants, written informed consent for the publication of the study results without disclosing their identities was sought.

Data Availability Statement: The raw data and materials used for this study are available upon request.

Acknowledgments: The authors are grateful to the participants and SUPER study staff members.

Conflicts of Interest: The authors declare no conflict of interest.

References

1. Bosia, M.; Buonocore, M.; Bechi, M.; Santarelli, L.; Spangaro, M.; Cocchi, F.; Guglielmino, C.; Bianchi, L.; Bringheli, S.; Bosinelli, F.; et al. Improving Cognition to Increase Treatment Efficacy in Schizophrenia: Effects of Metabolic Syndrome on Cognitive Remediation's Outcome. *Front. Psychiatry* **2018**, *9*, 647. [CrossRef]
2. Vacca, A.; Longo, R.; Mencar, C. Identification and evaluation of cognitive deficits in schizophrenia using "Machine learning". *Psychiatr. Danub.* **2019**, *31*, 261–264. [PubMed]
3. Anda, L.; Brønnick, K.K.; Johannessen, J.O.; Joa, I.; Kroken, R.A.; Johnsen, E.; Rettenbacher, M.; Fathian, F.; Løberg, E.-M. Cognitive Profile in Ultra High Risk for Psychosis and Schizophrenia: A Comparison Using Coordinated Norms. *Front. Psychiatry* **2019**, *10*, 695. [CrossRef] [PubMed]
4. Sheffield, J.M.; Karcher, N.R.; Barch, D.M. Cognitive Deficits in Psychotic Disorders: A Lifespan Perspective. *Neuropsychol. Rev.* **2018**, *28*, 509–533. [CrossRef]
5. Potvin, S.; Stavro, K.; Pelletier, J. Paradoxical Cognitive Capacities in Dual Diagnosis Schizophrenia: The Quest for Explanatory Factors. *J. Dual Diagn.* **2012**, *8*, 35–47. [CrossRef]
6. Manning, V.; Betteridge, S.; Wanigaratne, S.; Best, D.; Strang, J.; Gossop, M. Cognitive impairment in dual diagnosis inpatients with schizophrenia and alcohol use disorder. *Schizophr. Res.* **2009**, *114*, 98–104. [CrossRef] [PubMed]
7. Mohamed, S.; Bondi, M.W.; Kasckow, J.W.; Golshan, S.; Jeste, D.V. Neurocognitive functioning in dually diagnosed middle aged and elderly patients with alcoholism and schizophrenia. *Int. J. Geriatr. Psychiatry* **2006**, *21*, 711–718. [CrossRef]
8. Tyburski, E.; Pełka-Wysiecka, J.; Mak, M.; Samochowiec, A.; Bieńkowski, P.; Samochowiec, J. Neuropsychological Profile of Specific Executive Dysfunctions in Patients with Deficit and Non-deficit Schizophrenia. *Front. Psychol.* **2017**, *8*, 1459. [CrossRef]
9. Yu, M.; Tang, X.; Wang, X.; Zhang, X.; Zhang, X.; Sha, W.; Yao, S.; Shu, N.; Zhang, X.; Zhang, Z. Neurocognitive Impairments in Deficit and Non-Deficit Schizophrenia and Their Relationships with Symptom Dimensions and Other Clinical Variables. *PLoS ONE* **2015**, *10*, e0138357. [CrossRef]
10. Hartz, S.M.; Pato, C.N.; Medeiros, H.; Cavazos-Rehg, P.; Sobell, J.L.; Knowles, J.A.; Bierut, L.J.; Pato, M.T. Comorbidity of Severe Psychotic Disorders With Measures of Substance Use. *JAMA Psychiatry* **2014**, *71*, 248–254. [CrossRef]
11. Leposavić, L.; Dimitrijević, D.; Đorđević, S.; Leposavić, I.; Balkoski, G.N. Comorbidity of harmful use of alcohol in population of schizophrenic patients. *Psychiatr. Danub.* **2015**, *27*, 84–89. [PubMed]
12. Hunt, G.E.; Large, M.M.; Cleary, M.; Lai, H.M.X.; Saunders, J.B. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. *Drug Alcohol Depend.* **2018**, *191*, 234–258. [CrossRef] [PubMed]

13. Esser, M.B.; Hedden, S.L.; Kanny, D.; Brewer, R.D.; Gfroerer, J.C.; Naimi, T.S. Prevalence of Alcohol Dependence Among US Adult Drinkers, 2009–2011. *Prev. Chronic Dis.* **2014**, *11*, E206. [CrossRef]
14. Fat, L.N.; Bell, S.; Britton, A. A life-time of hazardous drinking and harm to health among older adults: Findings from the Whitehall II prospective cohort study. *Addiction* **2020**, *115*, 1855–1866. [CrossRef]
15. Fujii, H.; Nishimoto, N.; Yamaguchi, S.; Kurai, O.; Miyano, M.; Ueda, W.; Oba, H.; Naoki, N.; Kawada, N.; Okawa, K. The Alcohol Use Disorders Identification Test for Consumption (AUDIT-C) is more useful than pre-existing laboratory tests for predicting hazardous drinking: A cross-sectional study. *BMC Public Health* **2016**, *16*, 1–8. [CrossRef] [PubMed]
16. Rehm, J.; Anderson, P.; Manthey, J.; Shield, K.D.; Struzzo, P.; Wojnar, M.; Gual, A. Alcohol Use Disorders in Primary Health Care: What Do We Know and Where Do We Go? *Alcohol Alcohol.* **2016**, *51*, 422–427. [CrossRef]
17. Babor, T.F.; Longabaugh, R.; Zweben, A.; Fuller, R.K.; Stout, R.L.; Anton, R.F.; Randall, C.L. Issues in the definition and measurement of drinking outcomes in alcoholism treatment research. *J. Stud. Alcohol Suppl.* **1994**, *s12*, 101–111. [CrossRef]
18. Wilsnack, R.W.; Wilsnack, S.C.; Kristjanson, A.F.; Vogeltanz-Holm, N.D.; Gmel, G. Gender and alcohol consumption: Patterns from the multinational GENACIS project. *Addiction* **2009**, *104*, 1487–1500. [CrossRef]
19. Slade, T.; Chapman, C.; Swift, W.; Keyes, K.; Tonks, Z.; Teesson, M. Birth cohort trends in the global epidemiology of alcohol use and alcohol-related harms in men and women: Systematic review and metaregression. *BMJ Open* **2016**, *6*, e011827. [CrossRef]
20. Mäkelä, P.; Tigerstedt, C.; Mustonen, H. The Finnish drinking culture: Change and continuity in the past 40 years. *Drug Alcohol Rev.* **2012**, *31*, 831–840. [CrossRef]
21. Brennan, S.E.; McDonald, S.; Page, M.J.; Reid, J.; Ward, S.; Forbes, A.B.; McKenzie, J.E. Long-term effects of alcohol consumption on cognitive function: A systematic review and dose-response analysis of evidence published between 2007 and 2018. *Syst. Rev.* **2020**, *9*, 1–39. [CrossRef]
22. Rehm, J.; Hasan, O.S.M.; Black, S.E.; Shield, K.D.; Schwarzing, M. Alcohol use and dementia: A systematic scoping review. *Alzheimer's Res. Ther.* **2019**, *11*, 1–11. [CrossRef]
23. Koch, M.; Fitzpatrick, A.L.; Rapp, S.R.; Nahin, R.L.; Williamson, J.D.; Lopez, O.L.; DeKosky, S.T.; Kuller, L.H.; Mackey, R.H.; Mukamal, K.J.; et al. Alcohol Consumption and Risk of Dementia and Cognitive Decline Among Older Adults With or Without Mild Cognitive Impairment. *JAMA Netw. Open* **2019**, *2*, e1910319. [CrossRef] [PubMed]
24. Piumatti, G.; Moore, S.C.; Berridge, D.M.; Sarkar, C.; Gallacher, J. The relationship between alcohol use and long-term cognitive decline in middle and late life: A longitudinal analysis using UK Biobank. *J. Public Health* **2018**, *40*, 304–311. [CrossRef] [PubMed]
25. Pihlajamaa, J.; Suvisaari, J.; Henriksson, M.; Heilä, H.; Karjalainen, E.; Koskela, J.; Cannon, M.; Lönnqvist, J. The validity of schizophrenia diagnosis in the Finnish Hospital Discharge Register: Findings from a 10-year birth cohort sample. *Nord. J. Psychiatry* **2008**, *62*, 198–203. [CrossRef] [PubMed]
26. Frank, D.; DeBenedetti, A.F.; Volk, R.J.; Williams, E.; Kivlahan, D.R.; Bradley, K.A. Effectiveness of the AUDIT-C as a Screening Test for Alcohol Misuse in Three Race/Ethnic Groups. *J. Gen. Intern. Med.* **2008**, *23*, 781–787. [CrossRef]
27. Public Health England. Alcohol Use Screening Tests. 2017. Available online: <https://www.gov.uk/government/publications/alcohol-use-screening-tests> (accessed on 28 October 2020).
28. Lintonen, T.; Niemelä, S.; Mäkelä, P. Alkoholinkäytön hälytysrajan ylittäviä käyttäjiä on Suomessa vähintään viisi prosenttia väestöstä. *Lääketieteellinen Aikakauskirja Duodecim* **2019**, *135*, 1459–1466. Available online: <https://www.duodecimlehti.fi/lehti/2019/16/duo15071> (accessed on 28 October 2020).
29. Barnett, J.H.; Sahakian, B.J.; Werners, U.; Hill, K.E.; Brazil, R.; Gallagher, O.; Bullmore, E.T.; Jones, P.B. Visuospatial learning and executive function are independently impaired in first-episode psychosis. *Psychol. Med.* **2005**, *35*, 1031–1041. [CrossRef] [PubMed]
30. Taivalantti, M.; Barnett, J.H.; Halt, A.-H.; Koskela, J.; Auvinen, J.; Timonen, M.; Järvelin, M.-R.; Veijola, J. Depressive symptoms as predictors of visual memory deficits in middle-age. *J. Affect. Disord.* **2020**, *264*, 29–34. [CrossRef]
31. Van Hooren, S.A.H.; Valentijn, A.M.; Bosma, H.; Ponds, R.W.H.M.; Van Boxtel, M.P.J.; Jolles, J. Cognitive Functioning in Healthy Older Adults Aged 64–81: A Cohort Study into the Effects of Age, Sex, and Education. *Aging Neuropsychol. Cogn.* **2007**, *14*, 40–54. [CrossRef]
32. Biddle, K.D.; Jacobs, H.I.L.; Uquillas, F.D.; Zide, B.S.; Kirn, D.R.; Properzi, M.R.; Rentz, D.M.; Johnson, K.A.; Sperling, R.A.; Donovan, N.J. Associations of Widowhood and β -Amyloid With Cognitive Decline in Cognitively Unimpaired Older Adults. *JAMA Netw. Open* **2020**, *3*, e200121. [CrossRef]
33. Andersson, C.; Marklund, K.; Walles, H.; Hagman, G.; Miley-Akerstedt, A. Lifestyle Factors and Subjective Cognitive Impairment in Patients Seeking Help at a Memory Disorder Clinic: The Role of Negative Life Events. *Dement. Geriatr. Cogn. Disord.* **2019**, *48*, 196–206. [CrossRef]
34. Strandberg, A.Y.; Trygg, T.; Pitkälä, K.H.; E Strandberg, T. Alcohol consumption in midlife and old age and risk of frailty. *Age Ageing* **2018**, *47*, 248–254. [CrossRef]
35. Krahn, D.; Freese, J.; Hauser, R.; Barry, K.; Goodman, B. Alcohol Use and Cognition at Mid-Life: The Importance of Adjusting for Baseline Cognitive Ability and Educational Attainment. *Alcohol. Clin. Exp. Res.* **2003**, *27*, 1162–1166. [CrossRef]
36. Donovan, N.J.; Okereke, O.I.; Vannini, P.; Amariglio, R.E.; Rentz, D.M.; Marshall, G.A.; Johnson, K.A.; Sperling, R.A. Association of Higher Cortical Amyloid Burden With Loneliness in Cognitively Normal Older Adults. *JAMA Psychiatry* **2016**, *73*, 1230–1237. [CrossRef]
37. Bora, E. Neurodevelopmental origin of cognitive impairment in schizophrenia. *Psychol. Med.* **2015**, *45*, 1–9. [CrossRef]

38. Frangou, S. Cognitive function in early onset schizophrenia: A selective review. *Front. Hum. Neurosci.* **2009**, *3*, 79. [[CrossRef](#)] [[PubMed](#)]
39. Lee, J.K.; Son, Y.-J. Gender Differences in the Impact of Cognitive Function on Health Literacy among Older Adults with Heart Failure. *Int. J. Environ. Res. Public Health* **2018**, *15*, 2711. [[CrossRef](#)] [[PubMed](#)]
40. Voyer, D.; Voyer, S.D.; Saint-Aubin, J. Sex differences in visual-spatial working memory: A meta-analysis. *Psychon. Bull. Rev.* **2017**, *24*, 307–334. [[CrossRef](#)] [[PubMed](#)]
41. Herlitz, A.; Dekhtyar, S.; Asperholm, M.; Weber, D. Gender differences in memory and cognition. In *Encyclopedia of Geropsychology*; Springer: Singapore, 2016; pp. 1–7, ISBN 978-981-287-080-3. [[CrossRef](#)]
42. Hughes, T.L.; Wilsnack, S.C.; Kantor, L.W. The Influence of Gender and Sexual Orientation on Alcohol Use and Alcohol-Related Problems: Toward a Global Perspective. *Alcohol Res. Curr. Rev.* **2016**, *38*, 121–132.
43. Manning, V.; Wanigaratne, S.; Best, D.; Strathdee, G.; Schrover, I.; Gossop, M. Screening for cognitive functioning in psychiatric outpatients with schizophrenia, alcohol dependence, and dual diagnosis. *Schizophr. Res.* **2007**, *91*, 151–158. [[CrossRef](#)]
44. Thoma, R.J.; Hanlon, F.M.; Miller, G.A.; Huang, M.; Weisend, M.P.; Sanchez, F.P.; Waldorf, V.A.; Jones, A.; Smith, A.; Formoso, M.J.; et al. Neuropsychological and sensory gating deficits related to remote alcohol abuse history in schizophrenia. *J. Int. Neuropsychol. Soc.* **2006**, *12*, 34–44. [[CrossRef](#)] [[PubMed](#)]
45. Bowie, C.R.; Serper, M.R.; Riggio, S.; Harvey, P.D. Neurocognition, symptomatology, and functional skills in older alcohol-abusing schizophrenia patients. *Schizophr. Bull.* **2005**, *31*, 175–182. [[CrossRef](#)]
46. Allen, D.N.; Goldstein, G.; Forman, S.D.; Keshavan, M.S.; Van Kammen, D.P.; Sanders, R.D. Neurologic examination abnormalities in schizophrenia with and without a history of alcoholism. *Neuropsychiatry, Neuropsychol. Behav. Neurol.* **2000**, *13*, 184–187.
47. Buleyko, A.A.; Soldatkin, V.A.; Murina, I.V.; Ruban, D.A.; Simak, O.Y.; Krysenko, P.B.; Kryuchkova, M.N. Does alcohol influence the cognitive functions of schizophrenic patients? *Zhurnal Nevrol. Psikhiatrii Im S S Korsakova* **2019**, *119*, 14–19. [[CrossRef](#)] [[PubMed](#)]
48. Allen, D.N.; Goldstein, G.; Aldarondo, F. Neurocognitive dysfunction in patients diagnosed with schizophrenia and alcoholism. *Neuropsychology* **1999**, *13*, 62–68. [[CrossRef](#)]
49. Nixon, S.J.; Hallford, H.; Tivis, R.D. Neurocognitive function in alcoholic, schizophrenic, and dually diagnosed patients. *Psychiatry Res.* **1996**, *64*, 35–45. [[CrossRef](#)]
50. Gizewski, E.R.; Müller, B.W.; Scherbaum, N.; Lieb, B.; Forsting, M.; Wiltfang, J.; Leygraf, N.; Schiffer, B. The impact of alcohol dependence on social brain function. *Addict. Biol.* **2012**, *18*, 109–120. [[CrossRef](#)]
51. Potvin, S.; Mancini-Marie, A.; Fahim, C.; Mensour, B.; Stip, E. Processing of social emotion in patients with schizophrenia and substance use disorder: An fMRI study. *Soc. Neurosci.* **2007**, *2*, 106–116. [[CrossRef](#)]
52. Mancini-Marie, A.; Potvin, S.; Fahim, C.; Beauregard, M.; Mensour, B.; Stip, E. Neural correlates of the affect regulation model in schizophrenia patients with substance use history: A functional magnetic resonance imaging study. *J. Clin. Psychiatry* **2006**, *67*, 342–350. [[CrossRef](#)] [[PubMed](#)]
53. Carey, K.B.; Carey, M.P.; Simons, J.S. Correlates of substance use disorder among psychiatric outpatients: Focus on cognition, social role functioning, and psychiatric status. *J. Nerv. Ment. Dis.* **2003**, *191*, 300–308. [[CrossRef](#)]
54. Potvin, S.; Joyal, C.C.; Pelletier, J.; Stip, E. Contradictory cognitive capacities among substance-abusing patients with schizophrenia: A meta-analysis. *Schizophr. Res.* **2008**, *100*, 242–251. [[CrossRef](#)] [[PubMed](#)]
55. Thoma, P.; Daum, I. Comorbid substance use disorder in schizophrenia: A selective overview of neurobiological and cognitive underpinnings. *Psychiatry Clin. Neurosci.* **2013**, *67*, 367–383. [[CrossRef](#)] [[PubMed](#)]
56. Bartholow, B.D.; Fleming, K.A.; Wood, P.K.; Cowan, N.; Sauls, J.S.; Altamirano, L.; Miyake, A.; Martins, J.; Sher, K.J. Alcohol effects on response inhibition: Variability across tasks and individuals. *Exp. Clin. Psychopharmacol.* **2018**, *26*, 251–267. [[CrossRef](#)] [[PubMed](#)]
57. Mayhugh, R.E.; Moussa, M.N.; Simpson, S.L.; Lyday, R.G.; Burdette, J.H.; Porrino, L.J.; Laurienti, P.J. Moderate-Heavy Alcohol Consumption Lifestyle in Older Adults Is Associated with Altered Central Executive Network Community Structure during Cognitive Task. *PLoS ONE* **2016**, *11*, e0160214. [[CrossRef](#)] [[PubMed](#)]
58. Carrilho, P.E.M.; Dos Santos, M.B.M.; Piasecki, L.; Jorge, A.C. Doença de Marchiafava-Bignami: Uma rara entidade com prognóstico sombrio. *Rev. Bras. Ter. Intensiva* **2013**, *25*, 68–72. [[CrossRef](#)]
59. Kim, J.W.; Lee, D.Y.; Lee, B.C.; Jung, M.H.; Kim, H.; Choi, Y.S.; Choi, I.-G. Alcohol and Cognition in the Elderly: A Review. *Psychiatry Investig.* **2012**, *9*, 8–16. [[CrossRef](#)] [[PubMed](#)]
60. Moussa, M.N.; Simpson, S.L.; Mayhugh, R.E.; Grata, M.E.; Burdette, J.H.; Porrino, L.J.; Laurienti, P.J. Long-term moderate alcohol consumption does not exacerbate age-related cognitive decline in healthy, community-dwelling older adults. *Front. Aging Neurosci.* **2015**, *6*, 341. [[CrossRef](#)]
61. Sabia, S.; Elbaz, A.; Britton, A.; Bell, S.; Dugravot, A.; Shipley, M.; Kivimaki, M.; Singh-Manoux, A. Alcohol consumption and cognitive decline in early old age. *Neurology* **2014**, *82*, 332–339. [[CrossRef](#)]
62. Reas, E.; Laughlin, G.; Kritz-Silverstein, D.; Barrett-Connor, E.; McEvoy, L. Moderate, Regular Alcohol Consumption is Associated with Higher Cognitive Function in Older Community-Dwelling Adults. *J. Prev. Alzheimer's Dis.* **2016**, *3*, 105–113.
63. Panza, F.; Frisardi, V.; Seripa, D.; Logroscino, G.; Santamato, A.; Imbimbo, B.P.; Scafato, E.; Pilotto, A.; Solfrizzi, V. Alcohol consumption in mild cognitive impairment and dementia: Harmful or neuroprotective? *Int. J. Geriatr. Psychiatry* **2012**, *27*, 1218–1238. [[CrossRef](#)] [[PubMed](#)]

64. Bond, G.E.; Burr, R.; McCurry, S.M.; Graves, A.B.; Larson, E.B. Alcohol, aging, and cognitive performance in a cohort of Japanese Americans aged 65 and older: The Kame project. *Int. Psychogeriatr.* **2001**, *13*, 207–223. [[CrossRef](#)] [[PubMed](#)]
65. Spencer, R.L.; Hutchison, K.E. Alcohol, Aging, and the Stress Response. *Alcohol Res. Health* **1999**, *23*, 272–283. [[PubMed](#)]
66. Zhang, R.; Shen, L.; Miles, T.; Shen, Y.; Cordero, J.; Qi, Y.; Liang, L.; Li, C. Association of Low to Moderate Alcohol Drinking with Cognitive Functions From Middle to Older Age Among US Adults. *JAMA Netw. Open* **2020**, *3*, e207922. [[CrossRef](#)] [[PubMed](#)]
67. Ganguli, M.; Bilt, J.V.; Saxton, J.A.; Shen, C.; Dodge, H.H. Alcohol consumption and cognitive function in late life: A longitudinal community study. *Neurology* **2005**, *65*, 1210–1217. [[CrossRef](#)] [[PubMed](#)]
68. Britton, A.; Singh-Manoux, A.; Marmot, M. Alcohol Consumption and Cognitive Function in the Whitehall II Study. *Am. J. Epidemiol.* **2004**, *160*, 240–247. [[CrossRef](#)]
69. Sun, L.; Xu, H.; Zhang, J.; Li, W.; Nie, J.; Qiu, Q.; Liu, Y.; Fang, Y.; Yang, Z.; Li, X.; et al. Alcohol Consumption and Subclinical Findings on Cognitive Function, Biochemical Indexes, and Cortical Anatomy in Cognitively Normal Aging Han Chinese Population. *Front. Aging Neurosci.* **2018**, *10*, 182. [[CrossRef](#)]
70. Topiwala, A.; Allan, C.L.; Valkanova, V.; Zsoldos, E.; Filippini, N.; Sexton, C.; Mahmood, A.; Fooks, P.; Singh-Manoux, A.; E Mackay, C.; et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: Longitudinal cohort study. *BMJ* **2017**, *357*, j2353. [[CrossRef](#)]
71. Lobo, E.; Dufouil, C.; Marcos, G.; Quetglas, B.; Saz, P.; Guallar, E.; Lobo, A.; Workgroup, F.T.Z. Is There an Association Between Low-to-Moderate Alcohol Consumption and Risk of Cognitive Decline? *Am. J. Epidemiol.* **2010**, *172*, 708–716. [[CrossRef](#)]
72. Richard, E.L.; Kritiz-Silverstein, D.; Laughlin, G.A.; Fung, T.T.; Barrett-Connor, E.; McEvoy, L.K. Alcohol Intake and Cognitively Healthy Longevity in Community-Dwelling Adults: The Rancho Bernardo Study. *J. Alzheimer's Dis.* **2017**, *59*, 803–814. [[CrossRef](#)]
73. Parker, E.S.; A Parker, D.; Harford, T.C. Specifying the relationship between alcohol use and cognitive loss: The effects of frequency of consumption and psychological distress. *J. Stud. Alcohol* **1991**, *52*, 366–373. [[CrossRef](#)] [[PubMed](#)]
74. Davis, B.J.K.; Vidal, J.-S.; Garcia, M.; Aspelund, T.; Van Buchem, M.A.; Jónsdóttir, M.K.; Sigurdsson, S.; Harris, T.B.; Gudnason, V.; Launer, L.J.; et al. The Alcohol Paradox: Light-to-Moderate Alcohol Consumption, Cognitive Function, and Brain Volume. *J. Gerontol. Ser. A Biol. Sci. Med. Sci.* **2014**, *69*, 1528–1535. [[CrossRef](#)] [[PubMed](#)]
75. Vasiliadis, H.-M.; Payette, M.-C.; Berbiche, D.; Grenier, S.; Hudon, C. Cognitive decline and alcohol consumption adjusting for functional status over a 3-year period in French speaking community living older adults. *J. Public Health* **2019**, *41*, e177–e184. [[CrossRef](#)] [[PubMed](#)]
76. Day, A.M.; Kahler, C.W.; Ahern, D.C.; Clark, U.S. Executive Functioning in Alcohol Use Studies: A Brief Review of Findings and Challenges in Assessment. *Curr. Drug Abus. Rev.* **2015**, *8*, 26–40. [[CrossRef](#)] [[PubMed](#)]
77. Neafsey, E.J.; A Collins, M. Moderate alcohol consumption and cognitive risk. *Neuropsychiatr. Dis. Treat.* **2011**, *7*, 465–484. [[CrossRef](#)]
78. Kim, J.W.; Byun, M.S.; Yi, D.; Lee, J.H.; Ko, K.; Jeon, S.Y.; Sohn, B.K.; Lee, J.-Y.; Kim, Y.K.; A Shin, S.; et al. Association of moderate alcohol intake with in vivo amyloid-beta deposition in human brain: A cross-sectional study. *PLoS Med.* **2020**, *17*, e1003022. [[CrossRef](#)]
79. Wallach, J.D.; Serghiou, S.; Chu, L.; Egilman, A.C.; Vasiliou, V.; Ross, J.S.; Ioannidis, J.P.A. Evaluation of confounding in epidemiologic studies assessing alcohol consumption on the risk of ischemic heart disease. *BMC Med. Res. Methodol.* **2020**, *20*, 1–10. [[CrossRef](#)]
80. Emberson, J.R.; A Bennett, D. Effect of alcohol on risk of coronary heart disease and stroke: Causality, bias, or a bit of both? *Vasc. Health Risk Manag.* **2006**, *2*, 239–249. [[CrossRef](#)]
81. Wootton, R.E.; Greenstone, H.; Abdellaoui, A.; Denys, D.; Verweij, K.; Munafò, M.R.; Treur, J.L. Bidirectional effects between loneliness, smoking and alcohol use: Evidence from a Mendelian randomization study. *Addiction* **2020**, *116*, 400–406. [[CrossRef](#)]
82. Schutte, R.; Papageorgiou, M.; Najlah, M.; Huisman, H.W.; Ricci, C.; Zhang, J.; Milner, N.; Schutte, A.E. Drink types unmask the health risks associated with alcohol intake—Prospective evidence from the general population. *Clin. Nutr.* **2020**, *39*, 3168–3174. [[CrossRef](#)]
83. Trevisan, M.; Schisterman, E.; Mennotti, A.; Farchi, G.; Conti, S. Drinking pattern and mortality: The Italian Risk Factor and Life Expectancy pooling project. *Ann. Epidemiol.* **2001**, *11*, 312–319. [[CrossRef](#)]
84. Hakulinen, C.; Elovainio, M.; Batty, G.D.; Virtanen, M.; Kivimäki, M.; Jokela, M. Personality and alcohol consumption: Pooled analysis of 72,949 adults from eight cohort studies. *Drug Alcohol Depend.* **2015**, *151*, 110–114. [[CrossRef](#)]
85. Stephenson, M.; Barr, P.; Ksinan, A.; Aliev, F.; Latvala, A.; Viken, R.; Rose, R.; Kaprio, J.; Dick, D.; Salvatore, J.E. Which adolescent factors predict alcohol misuse in young adulthood? A co-twin comparisons study. *Addiction* **2020**, *115*, 877–887. [[CrossRef](#)] [[PubMed](#)]
86. Der, G.; Batty, G.D.; Deary, I.J. The association between IQ in adolescence and a range of health outcomes at 40 in the 1979 US National Longitudinal Study of Youth. *Intelligence* **2009**, *37*, 573–580. [[CrossRef](#)]
87. Cao, M.; Cui, B. Association of Educational Attainment with Adiposity, Type 2 Diabetes, and Coronary Artery Diseases: A Mendelian Randomization Study. *Front. Public Health* **2020**, *8*, 112. [[CrossRef](#)] [[PubMed](#)]
88. Zhou, T.; Sun, D.; Li, X.; Ma, H.; Heianza, Y.; Qi, L. Educational attainment and drinking behaviors: Mendelian randomization study in UK Biobank. *Mol. Psychiatry* **2019**, *25*, 1–12. [[CrossRef](#)]
89. Mugavin, J.; MacLean, S.; Room, R.; Callinan, S. Adult low-risk drinkers and abstainers are not the same. *BMC Public Health* **2020**, *20*, 37. [[CrossRef](#)] [[PubMed](#)]

90. Haber, J.R.; Harris-Olenak, B.; Burroughs, T.; Jacob, T. Residual Effects: Young Adult Diagnostic Drinking Predicts Late-Life Health Outcomes. *J. Stud. Alcohol Drugs* **2016**, *77*, 859–867. [\[CrossRef\]](#)
91. Saarni, S.I.; Joutsenniemi, K.; Koskinen, S.; Suvisaari, J.; Pirkola, S.; Sintonen, H.; Poikolainen, K.; Lönnqvist, J. Alcohol consumption, abstaining, health utility, and quality of life—a general population survey in finland. *Alcohol Alcohol.* **2008**, *43*, 376–386. [\[CrossRef\]](#) [\[PubMed\]](#)
92. Fillmore, K.M.; Stockwell, T.; Chikritzhs, T.; Bostrom, A.; Kerr, W. Moderate Alcohol Use and Reduced Mortality Risk: Systematic Error in Prospective Studies and New Hypotheses. *Ann. Epidemiol.* **2007**, *17*, S16–S23. [\[CrossRef\]](#)
93. Gémes, K.; Janszky, I.; Strand, L.B.; László, K.D.; Ahnve, S.; Vatten, L.J.; Dalen, H.; Mukamal, K.J. Light-moderate alcohol consumption and left ventricular function among healthy, middle-aged adults: The HUNT study. *BMJ Open* **2018**, *8*, e020777. [\[CrossRef\]](#) [\[PubMed\]](#)
94. Kilian, C.; Manthey, J.; Probst, C.; Brunborg, G.S.; Bye, E.K.; Ekholm, O.; Kraus, L.; Moskalewicz, J.; Sieroslawski, J.; Rehm, J. Why Is Per Capita Consumption Underestimated in Alcohol Surveys? Results from 39 Surveys in 23 European Countries. *Alcohol Alcohol.* **2020**, *55*, 554–563. [\[CrossRef\]](#)
95. Mukamal, K.J.; Jensen, M.K.; Grønbaek, M.; Stampfer, M.J.; Manson, J.E.; Pischon, T.; Rimm, E.B. Drinking Frequency, Mediating Biomarkers, and Risk of Myocardial Infarction in Women and Men. *Circulation* **2005**, *112*, 1406–1413. [\[CrossRef\]](#) [\[PubMed\]](#)
96. Wellmann, J.; Heidrich, J.; Berger, K.; Döring, A.; Heuschmann, P.U.; Keil, U. Changes in alcohol intake and risk of coronary heart disease and all-cause mortality in the MONICA/KORA-Augsburg cohort 1987–97. *Eur. J. Cardiovasc. Prev. Rehabil.* **2004**, *11*, 48–55. [\[CrossRef\]](#)
97. Wood, A.M.; Kaptoge, S.; Butterworth, A.S.; Willeit, P.; Warnakula, S.; Bolton, T.; Paige, E.; Paul, D.; Sweeting, M.; Burgess, S.; et al. Risk thresholds for alcohol consumption: Combined analysis of individual-participant data for 599 912 current drinkers in 83 prospective studies. *Lancet* **2018**, *391*, 1513–1523. [\[CrossRef\]](#)
98. Seid, A.K. Social interactions, trust and risky alcohol consumption. *Health Econ. Rev.* **2016**, *6*, 1–9. [\[CrossRef\]](#) [\[PubMed\]](#)
99. Beck, A.T.; Himelstein, R.; Bredemeier, K.; Silverstein, S.M.; Grant, P. What accounts for poor functioning in people with schizophrenia: A re-evaluation of the contributions of neurocognitive v. attitudinal and motivational factors. *Psychol. Med.* **2018**, *48*, 2776–2785. [\[CrossRef\]](#) [\[PubMed\]](#)
100. Moritz, S.; Irshaid, S.; Lüdtke, T.; Schäfer, I.; Hauschildt, M.; Lipp, M. Neurocognitive Functioning in Alcohol Use Disorder: Cognitive Test Results Do not Tell the Whole Story. *Eur. Addict. Res.* **2018**, *24*, 217–225. [\[CrossRef\]](#)
101. Campellone, T.R.; Sanchez, A.H.; Kring, A.M. Defeatist Performance Beliefs, Negative Symptoms, and Functional Outcome in Schizophrenia: A Meta-analytic Review. *Schizophr. Bull.* **2016**, *42*, 1343–1352. [\[CrossRef\]](#)
102. Charlton, A.J.; May, C.; Luikinga, S.J.; Burrows, E.L.; Kim, J.H.; Lawrence, A.J.; Perry, C.J. Chronic voluntary alcohol consumption causes persistent cognitive deficits and cortical cell loss in a rodent model. *Sci. Rep.* **2019**, *9*, 1–19. [\[CrossRef\]](#)
103. Galaj, E.; Kipp, B.; Floresco, S.; Savage, L. Persistent Alterations of Accumbal Cholinergic Interneurons and Cognitive Dysfunction after Adolescent Intermittent Ethanol Exposure. *Neuroscience* **2019**, *404*, 153–164. [\[CrossRef\]](#) [\[PubMed\]](#)
104. Cheng, Y.; Liu, X.; Ma, X.; Garcia, R.; Belfield, K.; Haorah, J. Alcohol promotes waste clearance in the CNS via brain vascular reactivity. *Free. Radic. Biol. Med.* **2019**, *143*, 115–126. [\[CrossRef\]](#)
105. Ayabe, T.; Fukuda, T.; Ano, Y. Improving Effects of Hop-Derived Bitter Acids in Beer on Cognitive Functions: A New Strategy for Vagus Nerve Stimulation. *Biomolecules* **2020**, *10*, 131. [\[CrossRef\]](#)
106. Ano, Y.; Takaichi, Y.; Uchida, K.; Kondo, K.; Nakayama, H.; Takashima, A. Iso- α -Acids, the Bitter Components of Beer, Suppress Microglial Inflammation in rTg4510 Tauopathy. *Molecules* **2018**, *23*, 3133. [\[CrossRef\]](#)
107. Lu, S.; Liao, L.; Zhang, B.; Yan, W.; Chen, L.; Yan, H.; Guo, L.; Lu, S.; Xiong, K.; Yan, J. Antioxidant cascades confer neuroprotection in ethanol, morphine, and methamphetamine preconditioning. *Neurochem. Int.* **2019**, *131*, 104540. [\[CrossRef\]](#) [\[PubMed\]](#)
108. Zhou, D.; Zhao, Y.; Hook, M.; Zhao, W.; Starlard-Davenport, A.; Cook, M.N.; Jones, B.C.; Hamre, K.M.; Lu, L. Ethanol's Effect on Coq7 Expression in the Hippocampus of Mice. *Front. Genet.* **2018**, *9*. [\[CrossRef\]](#) [\[PubMed\]](#)
109. Casañas-Sánchez, V.; Pérez, J.A.; Quinto-Aleman, D.; Díaz, M. Sub-toxic Ethanol Exposure Modulates Gene Expression and Enzyme Activity of Antioxidant Systems to Provide Neuroprotection in Hippocampal HT22 Cells. *Front. Physiol.* **2016**, *7*, 312. [\[CrossRef\]](#) [\[PubMed\]](#)
110. Pignataro, L. Alcohol protects the CNS by activating HSF1 and inducing the heat shock proteins. *Neurosci. Lett.* **2019**, *713*, 134507. [\[CrossRef\]](#) [\[PubMed\]](#)
111. Zhou, R.-P.; Leng, T.-D.; Yang, T.; Chen, F.-H.; Xiong, Z.-G. Acute Ethanol Exposure Promotes Autophagy-Lysosome Pathway-Dependent ASIC1a Protein Degradation and Protects Against Acidosis-Induced Neurotoxicity. *Mol. Neurobiol.* **2019**, *56*, 3326–3340. [\[CrossRef\]](#)
112. Su, F.; Guo, A.-C.; Li, W.-W.; Zhao, Y.-L.; Qu, Z.-Y.; Wang, Y.-J.; Wang, Q.; Zhu, Y.-L. Low-Dose Ethanol Preconditioning Protects Against Oxygen-Glucose Deprivation/Reoxygenation-Induced Neuronal Injury By Activating Large Conductance, Ca²⁺-Activated K⁺ Channels In Vitro. *Neurosci. Bull.* **2016**, *33*, 28–40. [\[CrossRef\]](#)
113. Larsson, S.C.; Burgess, S.; Mason, A.M.; Michaëlsson, K. Alcohol Consumption and Cardiovascular Disease. *Circ. Genom. Precis. Med.* **2020**, *13*, e002814. [\[CrossRef\]](#) [\[PubMed\]](#)
114. Millwood, I.Y.; Walters, R.G.; Mei, X.W.; Guo, Y.; Yang, L.; Bian, Z.; A Bennett, D.; Chen, Y.; Dong, C.; Hu, R.; et al. Conventional and genetic evidence on alcohol and vascular disease aetiology: A prospective study of 500,000 men and women in China. *Lancet* **2019**, *393*, 1831–1842. [\[CrossRef\]](#)

115. Christensen, A.I.; Nordestgaard, B.G.; Tolstrup, J.S. Alcohol Intake and Risk of Ischemic and Haemorrhagic Stroke: Results from a Mendelian Randomisation Study. *J. Stroke* **2018**, *20*, 218–227. [[CrossRef](#)]
116. Kumari, M.; Holmes, M.V.; Dale, C.E.; Hubacek, J.A.; Palmer, T.M.; Pikhart, H.; Peasey, A.; Britton, A.; Horvat, P.; Kubinova, R.; et al. Alcohol consumption and cognitive performance: A Mendelian randomization study. *Addiction* **2014**, *109*, 1462–1471. [[CrossRef](#)] [[PubMed](#)]
117. Clarke, T.-K.; Adams, M.J.; Davies, G.; Howard, D.M.; Hall, L.S.; Padmanabhan, S.; Murray, A.D.; Smith, B.H.; Campbell, A.; Hayward, C.; et al. Genome-wide association study of alcohol consumption and genetic overlap with other health-related traits in UK Biobank (N = 112 117). *Mol. Psychiatry* **2017**, *22*, 1376–1384. [[CrossRef](#)] [[PubMed](#)]
118. Ho, B.C.; Magnotta, V. Hippocampal volume deficits and shape deformities in young biological relatives of schizophrenia probands. *Neuroimage* **2010**, *49*, 3385–3393. [[CrossRef](#)]
119. Haijma, S.V.; Van Haren, N.; Cahn, W.; Koolschijn, P.C.M.P.; Pol, H.E.H.; Kahn, R.S. Brain Volumes in Schizophrenia: A Meta-Analysis in Over 18 000 Subjects. *Schizophr. Bull.* **2012**, *39*, 1129–1138. [[CrossRef](#)]
120. Lawrie, S.M.; Abukmeil, S.S. Brain abnormality in schizophrenia. *Br. J. Psychiatry* **1998**, *172*, 110–120. [[CrossRef](#)]
121. Lawrie, S.M. Are structural brain changes in schizophrenia related to antipsychotic medication? A narrative review of the evidence from a clinical perspective. *Ther. Adv. Psychopharmacol.* **2018**, *8*, 319–326. [[CrossRef](#)]